What future for cannabis?

April 16, 2003

The potential therapeutic effects of cannabis are outlined in a review in the May issue of THE LANCET NEUROLOGY. The review is published in anticipation of results from randomised trials expected later this year investigating possible benefits of the drug for people with multiple sclerosis. The first cannabis-based medicines are currently being considered for license.

Cannabis is the third most popular recreational drug after alcohol and tobacco. The history, biological/pharmacological effects, and current research investigating its potential therapeutic benefits are outlined by Alan Thompson and David Baker from the Institute of Neurology, London, UK, and colleagues. They comment how--in addition to the research into multiple sclerosis--basic research is enabling the discovery that some cannabis compounds have previously unknown qualities--notably that cannabis could play a role in preventing neurodegeneration with implications for the future management of disorders such as Huntington's, Parkinson's, Alzheimer's, and motor-neuron diseases

Alan Thompson concludes: "As we learn more about the pharmacological activities of compounds in cannabis and their biological targets outside the cannabinoid system, varieties of cannabis might be tailored to different diseases or used in combination with known drugs. Whatever the future holds, there are many challenges to be overcome before we view cannabinoids as routine medicine in neurological disorders."
-end-
Contact: Professor Alan J Thompson, Neurological Outcome Measures Unit, Institute of Neurology, Queen Square, London WC1N 3BG, UK;
T) 44-207-837-3611 x4152;
F) 44-207-813-6505.

Lancet

Related Multiple Sclerosis Articles from Brightsurf:

New therapy improves treatment for multiple sclerosis
A new therapy that binds a cytokine to a blood protein shows potential in treating multiple sclerosis, and may even prevent it.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

New therapeutic options for multiple sclerosis in sight
Strategies for treating multiple sclerosis have so far focused primarily on T and B cells.

Diet has an impact on the multiple sclerosis disease course
The short-chain fatty acid propionic acid influences the intestine-mediated immune regulation in people with multiple sclerosis (MS).

The gut may be involved in the development of multiple sclerosis
It is incompletely understood which factors in patients with multiple sclerosis act as a trigger for the immune system to attack the brain and spinal cord.

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

7T MRI offers new insights into multiple sclerosis
Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI -- a far more powerful imaging technology -- to further examine LME in MS patients

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.

Read More: Multiple Sclerosis News and Multiple Sclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.